Skip to main content

Advertisement

SpringerLink
Log in

Eotaxins and C–C chemokine receptor type 3 in Parkinson’s disease

  • Original article
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

Abstract

Parkinson’s disease (PD) is one of the most common neuroinflammatory disorders and inflammatory processes seem to play an important role in the pathogenesis of PD. Chemokines as inflammatory mediators, which are involved in the recruitment of leukocytes, can play a role in the pathogenesis of PD. The aim of this study was to examine the serum level of eotaxins (CCL11, CCL24, and CCL26) and the expression of C–C chemokine receptor type 3 (CCR3) in patients with PD compared with healthy subjects. In this study, we measured the serum levels of CCL11, CCL24, and CCL26 with ELISA. In addition, gene and protein expression of CCR3 were measured by RT-PCR and flow cytometry techniques in PD patients (n = 30) and age- and sex-matched healthy subjects (n = 30). All patients suffering from PD were assessed clinically through Unified Parkinson’s Disease Rating Scale, Motor Examination (UPDRS ME). The results of this study showed that there was no significant alteration in the serum level of these chemokines and also their receptor among patients with PD and healthy subjects. No significant correlation was observed between the eotaxins serum levels and the clinical measures of PD severity. Based on the results, it can be concluded that eotaxins cannot be considered as appropriate targets for the diagnosis or treatment of PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Spillantini MG et al., α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci, 1998. 95(11): p. 6469–6473

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Petzinger GM et al (2013) Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson’s disease. Lancet Neurol 12(7):716–726

    PubMed  PubMed Central  Google Scholar 

  3. Ouchi Y et al (2005) Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 57(2):168–175

    CAS  PubMed  Google Scholar 

  4. Scalzo P et al (2011) Serum levels of chemokines in Parkinson’s disease. Neuroimmunomodulation 18(4):240–244

    CAS  PubMed  Google Scholar 

  5. Hanisch U-K, Kettenmann H (2007) Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10(11):1387

    CAS  PubMed  Google Scholar 

  6. Kim YS, Joh TH (2006) Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson’s disease. Exp Mol Med 38(4):333

    CAS  PubMed  Google Scholar 

  7. Block ML, Hong J-S (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76(2):77–98

    CAS  PubMed  Google Scholar 

  8. Perry VH, Nicoll JA, Holmes C (2010) Microglia in neurodegenerative disease. Nat Rev Neurol 6(4):193

    PubMed  Google Scholar 

  9. Ramesh G, MacLean AG, Philipp MT (2013) Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediat Inflamm 2013:1–20

    Google Scholar 

  10. Chemokine C (2002) Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 22:1067–1068

    Google Scholar 

  11. Ahmadi Z et al (2016) An overlook to the characteristics and roles played by eotaxin network in the pathophysiology of food allergies: allergic asthma and atopic dermatitis. Inflammation 39(3):1253–1267

    CAS  PubMed  Google Scholar 

  12. Ponath PD et al (1996) Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 183(6):2437–2448

    CAS  PubMed  Google Scholar 

  13. Kitaura M et al (1996) Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J Biol Chem 271(13):7725–7730

    CAS  PubMed  Google Scholar 

  14. Rentzos M et al (2007) Circulating interleukin-15 and RANTES chemokine in Parkinson’s disease. Acta Neurol Scand 116(6):374–379

    CAS  PubMed  Google Scholar 

  15. Reale M et al (2009) Peripheral cytokines profile in Parkinson’s disease. Brain Behav Immun 23(1):55–63

    CAS  PubMed  Google Scholar 

  16. Shimoji M et al (2009) CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson’s disease. Neurotox Res 16(3):318–328

    CAS  PubMed  Google Scholar 

  17. Parajuli B et al (2015) CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia. Glia 63(12):2274–2284

    PubMed  Google Scholar 

  18. König K et al (2015) Cytokine profiles in nasal fluid of patients with seasonal or persistent allergic rhinitis. Allergy Asthma Clin Immunol 11(1):26

    PubMed  PubMed Central  Google Scholar 

  19. Wittig HJ et al (1980) Age-related serum immunoglobulin E levels in healthy subjects and in patients with allergic disease. J Allergy Clin Immunol 66(4):305–313

    CAS  PubMed  Google Scholar 

  20. Graham J (2002) Isolation of human polymorphonuclear leukocytes (granulocytes) from a leukocyte-rich fraction. Sci World J 2:1393–1396

    CAS  Google Scholar 

  21. Heneka MT, Kummer MP, Latz E (2014) Innate immune activation in neurodegenerative disease. Nat Rev Immunol 14(7):463

    CAS  PubMed  Google Scholar 

  22. Amor S et al (2010) Inflammation in neurodegenerative diseases. Immunology 129(2):154–169

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Tran PB, Miller RJ (2003) Chemokine receptors: signposts to brain development and disease. Nat Rev Neurosci 4(6):444

    CAS  PubMed  Google Scholar 

  24. Michael B et al (2013) Post-acute serum eosinophil and neutrophil-associated cytokine/chemokine profile can distinguish between patients with neuromyelitis optica and multiple sclerosis; and identifies potential pathophysiological mechanisms—a pilot study. Cytokine 64(1):90–96

    CAS  PubMed  Google Scholar 

  25. Tanaka M et al (2008) Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology 71(13):974–981

    CAS  PubMed  Google Scholar 

  26. Mena MA, García de J, Yébenes (2008) Glial cells as players in parkinsonism: the “good,” the “bad,” and the “mysterious” glia. Neuroscientist 14(6):544–560

    CAS  PubMed  Google Scholar 

  27. Dobbs R et al (1999) Association of circulating TNF-α and IL-6 with ageing and parkinsonism. Acta Neurol Scand 100(1):34–41

    CAS  PubMed  Google Scholar 

  28. McGeer PL, McGeer EG (2008) The α-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease. Exp Neurol 212(2):235–238

    CAS  PubMed  Google Scholar 

  29. Selikhova M et al (2002) Impaired production of plasma interleukin-6 in patients with Parkinson’s disease. Bull Exp Biol Med 133(1):81–83

    CAS  PubMed  Google Scholar 

  30. Baba Y et al (2005) Alterations of T-lymphocyte populations in Parkinson disease. Park Relat Disord 11(8):493–498

    Google Scholar 

  31. Xanthou G et al (2003) CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. Eur J Immunol 33(8):2241–2250

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This project was supported by Rafsanjan University of Medical Sciences.

Author information

Authors and Affiliations

  1. Non Communicable Diseases Research Center, Rafsanjan University of Medical Science, Rafsanjan, Iran

    Amir Moghadam-Ahmadi

  2. Geriatric Care Research Center, Rafsanjan University of Medical Science, Rafsanjan, Iran

    Alireza Vakilian

  3. Neurology Department, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

    Amir Moghadam-Ahmadi, Sasan Shahsavari, Ali Moadab & Alireza Vakilian

  4. Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

    Hossein Khorramdelazad & Gholamhossein Hassanshahi

  5. Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

    Hossein Khorramdelazad & Gholamhossein Hassanshahi

Authors
  1. Amir Moghadam-Ahmadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hossein Khorramdelazad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gholamhossein Hassanshahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sasan Shahsavari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ali Moadab
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alireza Vakilian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alireza Vakilian.

Ethics declarations

Conflict of interest

All of the authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moghadam-Ahmadi, A., Khorramdelazad, H., Hassanshahi, G. et al. Eotaxins and C–C chemokine receptor type 3 in Parkinson’s disease. Acta Neurol Belg 120, 589–594 (2020). https://doi.org/10.1007/s13760-018-01061-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13760-018-01061-8

Keywords

Search

Navigation